-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

BRIEF-Ultragenyx Reports Preliminary 2022 Revenue Guidance For 2023 Revenue And Cash Usage Pipeline Updates And 2023 Milestones

Reuters · 01/06/2023 16:02
BRIEF-Ultragenyx Reports Preliminary 2022 Revenue Guidance For 2023 Revenue And Cash Usage Pipeline Updates And 2023 Milestones

- Ultragenyx Pharmaceutical Inc RARE.O:

  • ULTRAGENYX REPORTS PRELIMINARY 2022 REVENUE; GUIDANCE FOR 2023 REVENUE AND CASH USAGE; PIPELINE UPDATES AND 2023 MILESTONES

  • ULTRAGENYX PHARMACEUTICAL INC - PRELIMINARY 2022 TOTAL PRODUCT REVENUE OF $352 MILLION TO $356 MILLION

  • ULTRAGENYX PHARMACEUTICAL INC - 2023 EXPECTED TOTAL PRODUCT REVENUE GUIDANCE BETWEEN $425 MILLION TO $450 MILLION

  • ULTRAGENYX PHARMACEUTICAL INC - YEAR-END 2022 CASH BALANCE OF ABOUT $900 MILLION

  • ULTRAGENYX PHARMACEUTICAL INC - 2023 GUIDANCE FOR NET CASH USED IN OPERATIONS EXPECTED TO BE LESS THAN $400 MILLION

  • ULTRAGENYX PHARMACEUTICAL INC - CASH, CASH EQUIVALENTS, AND AVAILABLE-FOR-SALE INVESTMENTS WERE APPROXIMATELY $900 MILLION AS OF DECEMBER 31, 2022

Source text for Eikon: ID:

Further company coverage: RARE.O


((Reuters.Briefs@thomsonreuters.com;;))